GSK PLC
GSK: XLON (GBR)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
GBX 9,282.00 | Qbgf | Lvbnwrycl |
Glaxo Acquires Affinivax, Gaining an Intriguing Clinical Pneumococcal Vaccine at a Reasonable Price
Glaxo’s over $2 billion acquisition of Affinivax yields an intriguing late-stage pneumococcal vaccine at a reasonable price, but we don’t expect any major changes to our fair value estimate based on the transaction. The deal shows the strength of Glaxo to bring in external innovation to reinforce its pipeline, a key element to Glaxo’s wide moat.